Focus: Bicycle Therapeutics is a Cambridge-based biotechnology company specializing in bicyclic peptide therapeutics for oncology and other indications. The company operates as a focused mid-stage biotech with a proprietary peptide platform technology.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
7 added, 6 removed. Backfill posture.
Suited for scientists and technical professionals seeking deep platform expertise and startup-like autonomy; less ideal for those needing near-term regulatory catalysts or broad internal mobility.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Bicycle Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Bicycle Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: Context Therapeutics Inc. (CNTX) (CIK 0001842952) — EX-99.1
EX-99.1
8-K Filing: BICYCLE THERAPEUTICS PLC (BCYC) (CIK 0001761612) — EXHIBIT 99.1
EXHIBIT 99.1
8-K Filing: Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097) — EX-99.2
EX-99.2
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo